Document Detail

Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy.
MedLine Citation:
PMID:  10711553     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the cost-effectiveness of treatment with intramuscular (IM) methotrexate compared with fallopian tube-sparing laparoscopy for small unruptured ectopic pregnancy. METHODS: A decision-analytic model accounting for varying resolution rates, complication rates, and cost estimates was built to compare the use of methotrexate with laparoscopy. Meta-analysis results of studies identified by a MEDLINE search for IM methotrexate resolution rates and tube-sparing laparoscopy resolution rates were used in model estimation. A similar process was used to generate model complication rates. Data on associated resource use were derived from established clinical guidelines. Estimates of 1998 costs incurred by provider organizations were calculated using data from a large managed care organization. RESULTS: The average methotrexate resolution rate among the studies included was 87% (range 75-90%). The average laparoscopy resolution rate was 91% (range 72-100%). Complication rates for methotrexate ranged from 0% to 22%, with an average of 10% for minor complications, and from 0% to 11% for serious complications, with an average of 7%. Complication rates for laparoscopy ranged from 0% to 8% for intraoperative complications, with an average of 2%, and from 0% to 15% for postoperative complications, with an average of 9%. Baseline model estimates indicated an average cost saving of more than $3000 per resolved ectopic pregnancy with methotrexate treatment compared with laparoscopy. Results of extensive sensitivity analyses supported the finding of a cost saving with methotrexate treatment. CONCLUSION: Single-dose methotrexate is a cost-saving, nonsurgical, fallopian tube-sparing treatment for ectopic pregnancy.
R J Morlock; J E Lafata; D Eisenstein
Related Documents :
21790953 - Metastatic choriocarcinoma presenting and treated during viable pregnancy: a case report.
16391963 - Effect of pregnancy on effectiveness of laparoscopic nissen fundoplication.
3761413 - Thermal and heart rate response to ultrasonic exposure in the second and third trimeste...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  95     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-03-22     Completed Date:  2000-03-22     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  407-12     Citation Subset:  AIM; IM    
Henry Ford Health System, Detroit, Michigan 48202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / administration & dosage,  economics*,  therapeutic use
Cost Savings
Cost-Benefit Analysis
Laparoscopy / economics*
Methotrexate / administration & dosage,  economics*,  therapeutic use
Models, Economic*
Postoperative Complications
Pregnancy, Ectopic / drug therapy,  economics*,  surgery
United States
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Direct transport of progesterone from vagina to uterus.
Next Document:  Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvov...